<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400748</url>
  </required_header>
  <id_info>
    <org_study_id>15</org_study_id>
    <nct_id>NCT03400748</nct_id>
  </id_info>
  <brief_title>ANET Electrosurgery Applicator Pilot Evaluation Study</brief_title>
  <official_title>ANET Electrosurgery Applicator Pilot Evaluation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spiration, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spiration, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET&#xD;
      device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single arm, single center study that will evaluate the&#xD;
      effectiveness of the ANET Electrosurgery Applicator in up to 10 subjects.&#xD;
&#xD;
      Subjects who consent to participate in this study will have a lung tumor that is scheduled to&#xD;
      be removed surgically as part of their normal treatment. During the surgical procedure, just&#xD;
      prior to resection the subject's tumor will be treated with the ANET device. The ANET device&#xD;
      uses a bronchoscope to reach the tumor. Ultrasound on the bronchoscope, CT, and X-rays are&#xD;
      used to make sure the ANET device is in the tumor. Once in the tumor, the ANET device uses&#xD;
      radio-frequency (RF) ablation to treat the tumor. After standard surgical resection the tumor&#xD;
      and surrounding tissue is evaluated to characterize the effect of the ANET.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    business reason&#xD;
  </why_stopped>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">November 18, 2020</completion_date>
  <primary_completion_date type="Actual">November 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ANET Related Peri-procedural Adverse Events</measure>
    <time_frame>Day 0</time_frame>
    <description>The incidence of reported adverse events and serious adverse events related to the ANET device or procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>RF Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RF Ablation</intervention_name>
    <description>The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.</description>
    <arm_group_label>RF Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject with Stage I or Stage II primary lung cancer or metastatic lung tumor&#xD;
&#xD;
          2. Pathological proof of target nodule/tumor type and malignancy&#xD;
&#xD;
          3. Target nodule/tumor which can be accessed via EBUS bronchoscopy&#xD;
&#xD;
          4. Resection/surgical candidate&#xD;
&#xD;
          5. Participants must be at least 18 years old and able to provide consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subjects in whom flexible bronchoscopy is contraindicated&#xD;
&#xD;
          2. Target nodule &lt; 1.0 cm&#xD;
&#xD;
          3. Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor&#xD;
&#xD;
          4. Any comorbidity that the investigator feels would interfere with the safety of the&#xD;
             subject or the evaluation of study objectives&#xD;
&#xD;
          5. Pacemaker, implantable cardioverter, or other electronic implantable device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <results_first_submitted>June 25, 2021</results_first_submitted>
  <results_first_submitted_qc>September 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2021</results_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrosurgery</keyword>
  <keyword>RF ablation</keyword>
  <keyword>Minimally invasive</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>Lung metastasis</keyword>
  <keyword>Lung tumor</keyword>
  <keyword>Primary</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Endobronchial ultrasound</keyword>
  <keyword>EBUS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: Canada</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03400748/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: United States</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03400748/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RF Ablation</title>
          <description>Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.&#xD;
RF Ablation: The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RF Ablation</title>
          <description>Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.&#xD;
RF Ablation: The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="51" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ANET Related Peri-procedural Adverse Events</title>
        <description>The incidence of reported adverse events and serious adverse events related to the ANET device or procedure</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RF Ablation</title>
            <description>Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.&#xD;
RF Ablation: The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.</description>
          </group>
        </group_list>
        <measure>
          <title>ANET Related Peri-procedural Adverse Events</title>
          <description>The incidence of reported adverse events and serious adverse events related to the ANET device or procedure</description>
          <units>Adverse Event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RF Ablation</title>
          <description>Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.&#xD;
RF Ablation: The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lauri DeVore</name_or_title>
      <organization>Spiration, Inc.</organization>
      <phone>425-636-5464</phone>
      <email>lauri.devore@olympus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

